{"description":"Serious AEs and Other AEs were not collected for this study. Only All-Cause Mortality was monitored.","eventGroups":[{"deathsNumAffected":16,"deathsNumAtRisk":25,"description":"Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine (AZC): Given IV or SC\n\nDecitabine: Given IV or SC\n\nQuality-of-Life Assessment: Ancillary studies","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Arm A (Decitabine or Azacitidine)"},{"deathsNumAffected":14,"deathsNumAtRisk":25,"description":"Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.\n\nQuality-of-Life Assessment: Ancillary studies","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Arm B (Induction-like Chemotherapy Regimen)"}],"frequencyThreshold":"0","timeFrame":"All-Cause Mortality was assessed up to 18 months from start of treatment."}